|
Keliximab
|
凱利昔單抗
|
174722-30-6
|
|
Motavizumab
|
莫維珠單抗
|
677010-34-3
|
|
Apolizumab
|
阿泊珠單抗
|
267227-08-7
|
|
CNQX
|
|
115066-14-3
|
|
Basiliximab
|
巴利昔單抗
|
179045-86-4
|
|
Cl-Amidine
|
|
1043444-18-3
|
|
RAD51-IN-17
|
|
2101739-18-6
|
|
Vimseltinib
|
|
1628606-05-2
|
|
Galiximab
|
加利昔單抗
|
357613-77-5
|
|
dupilumab
|
度匹魯單抗
|
1190264-60-8
|
|
4-(2-Acetamido-4-fluoro-5-methylphenyl)butanoic acid
|
4-(2-乙酰氨基-4-氟-5-甲基苯基)丁酸
|
182182-28-1
|
|
BAY-1830839
|
|
1931994-80-7
|
|
Narsoplimab
|
納索利單抗
|
2108782-45-0
|
|
Igovomab
|
伊戈伏單抗
|
171656-50-1
|
|
Pexelizumab
|
培克珠單抗
|
219685-93-5
|
|
RIPA-56
|
|
1956370-21-0
|
|
Briakinumab
|
布雷奴單抗
|
339308-60-0
|
|
Supinoxin
|
|
888478-45-3
|
|
N,N-(3-Fluoro-4-methyl-8-oxo-5,6,7,8-tetrahydronaphthalene-1,7-diyl)diacetamide
|
N,N'-(3-氟-4-甲基-8-氧代-5,6,7,8-四氫萘-1,7-二基)二乙酰胺
|
143655-70-3
|
|
ADH-503
|
|
2055362-74-6
|
|
Fmoc-Gly-Gly-Phe-OtBu
|
|
236426-37-2
|
|
Abemaciclib Metabolites M2
|
|
1231930-57-6
|
|
Ganitumab
|
加尼妥單抗
|
905703-97-1
|
|
RMC-4630
|
|
2172652-48-9
|
|
Afelimomab
|
阿非莫單抗
|
156227-98-4
|
|
Clenoliximab
|
克立昔單抗
|
182912-58-9
|
|
Bertilimumab
|
柏替木單抗
|
375348-49-5
|
|
GV-58
|
|
1402821-41-3
|
|
1A-116
|
|
1430208-73-3
|
|
Amatuximab
|
阿麥妥單抗
|
931402-35-6
|
|
BMS 986299
|
|
2242952-69-6
|
|
PRL-3 Inhibitor I
|
|
893449-38-2
|
|
Metelimumab
|
美替木單抗
|
272780-74-2
|
|
ITI-214(phosphate）
|
|
1642303-38-5
|
|
Cedelizumab
|
西利珠單抗
|
156586-90-2
|
|
Lefamulin Acetate
|
醋酸來法莫林
|
1350636-82-6
|
|
N-(3-Fluoro-4-methyl-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
|
N-(3-氟-4-甲基-8-氧代-5,6,7,8-四氫-1-萘基)乙酰胺
|
143655-58-7
|
|
MC-Gly-Gly-Phe
|
|
1599440-15-9
|
|
OATD01
|
|
2088453-21-6
|
|
Mapatumumab
|
馬帕木單抗
|
658052-09-6
|
|
Milatuzumab
|
米拉組單抗
|
899796-83-9
|
|
F-901318
|
|
1928707-56-5
|
|
Vodobatinib
|
|
1388803-90-4
|
|
Senaparib
|
|
1401682-78-7
|
|
Tralokinumab
|
曲羅蘆單抗
|
1044515-88-9
|
|
Bunamidine HCl
|
|
1055-55-6
|
|
GSK-1520489A
|
|
1042433-41-9
|
|
Dimethyl carbate
|
|
39589-98-5
|
|
LY 2979165
|
|
1311385-35-9
|
|
Efalizumab
|
依法珠單抗
|
214745-43-4
|
|
CFI-401870
|
|
1430741-35-7
|
|
Mitumomab
|
米妥莫單抗
|
216503-58-1
|
|
Labetuzumab
|
拉貝珠單抗
|
219649-07-7
|
|
(EZ)-GO289
|
|
694522-87-7
|
|
IM156
|
|
1422365-94-3
|
|
Lintuzumab
|
林妥珠單抗
|
166089-32-3
|
|
Tafenoquine succinate
|
他非諾喹琥珀酸鹽
|
106635-81-8
|
|
Lerdelimumab
|
樂德木單抗
|
285985-06-0
|
|
Tadocizumab
|
他度組單抗
|
339086-80-5
|
|
Ilginatinib
|
|
1239358-86-1
|
|
CX-1632
|
|
1038984-31-4
|
|
Dynarrestin
|
|
2222768-84-3
|
|
Sacituzumab
|
沙西妥珠單抗
|
1796566-95-4
|
|
Tositumomab
|
托西莫單抗
|
208921-02-2
|
|
Spongosine
|
|
24723-77-1
|
|
Oregovomab
|
奧戈伏單抗
|
213327-37-8
|
|
LGD-6972
|
|
1207989-09-0
|
|
Gavilimomab
|
加維莫單抗
|
244096-20-6
|
|
BAY85-8501
|
|
1161921-82-9
|
|
ADX-102
|
|
916056-79-6
|
|
Elinzanetant
|
|
929046-33-3
|
|
Siltuximab
|
塞妥昔單抗
|
541502-14-1
|
|
LM11A-31
|
|
289475-77-0
|
|
Fresolimumab
|
非蘇木單抗
|
948564-73-6
|
|
ABAGOVOMAB
|
阿巴伏單抗
|
792921-10-9
|
|
Otilimab
|
|
1638332-55-4
|
|
Lumiliximab
|
魯昔單抗
|
357613-86-6
|
|
ADH-503
|
|
2055362-72-4
|
|
Lexatumumab
|
來沙木單抗
|
845816-02-6
|
|
WIN54954
|
|
107355-45-3
|
|
Inolimomab
|
伊諾莫單抗
|
152981-31-2
|
|
Teclozan
|
|
5560-78-1
|
|
Eliapixant
|
|
1948229-21-7
|
|
Biciromab
|
比西單抗
|
138783-13-8
|
|
SU4984
|
|
186610-89-9
|
|
Bavituximab
|
巴維昔單抗
|
648904-28-3
|
|
TL895
|
|
1415823-49-2
|
|
Felvizumab
|
泛維珠單抗
|
167747-20-8
|
|
Imciromab
|
英西單抗
|
126132-83-0
|
|
Zabedosertib
|
|
1931994-81-8
|
|
Nofetumomab
|
諾非妥莫單抗
|
165942-79-0
|
|
N-(3-Fluoro-4-methyl-5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
|
N-(3-氟-4-甲基-5-氧代-5,6,7,8-四氫-1-萘基)乙酰胺
|
182182-29-2
|
|
JNJ38877605
|
|
943540-74-7
|
|
Siplizumab
|
西利珠單抗
|
288392-69-8
|
|
Edobacomab
|
埃巴單抗
|
141410-98-2
|
|
Lu-AF27139
|
|
2097117-06-9
|
|
M-8891
|
|
1464842-09-8
|
|
Tuvirumab
|
妥韋單抗
|
138660-97-6
|
|
Meplazumab
|
美珀珠單抗
|
2413715-21-4
|
|
Sulesomab
|
硫索單抗
|
167747-19-5
|